Sévérine de Bruijn

Ms. Sévérine de Bruijn


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2021 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
SBSévérine de Bruijn
Sévérine de Bruijn
MMMarie‐Berthe Maes
Marie‐Berthe Maes
LWLaure De Waele
Laure De Waele
KVKaren Vanhoorelbeke
Karen Vanhoorelbeke
AGAlain Gadisseur
Alain Gadisseur

20 March 2017 in Journal of Clinical and Translational Hepatology
Verified
Journal Article
Open access
PDF file
SBSévérine de Bruijn
Sévérine de Bruijn
EPEster Philipse
Ester Philipse
MCMarie Madeleine Couttenye
Marie Madeleine Couttenye
BBBart Bracke
Bart Bracke
DYDirk Ysebaert
Dirk Ysebaert
AVAnke Verlinden
Anke Verlinden
Background and Aims: Due to the shortage of donor livers, minor ABO-incompatible liver transplantations are commonly performed. Together with the allograft, immunocompetent B-lymphocytes, called passenger lymphocytes, are transplanted. In case of minor ABO-incompatibility, these passenger lymphocytes produce antibodies directed towards the recipient’s red blood cells, which causes immune-mediated hemolysis, also known as the passenger lymphocyte syndrome (PLS). Although this is a self-limiting disorder, serious complications can occur, including graft failure. Retrospectively, we evaluated the role of PLS in minor ABO-incompatible liver transplantations performed at our center.

19 September 2019 in Cancers
Verified
Journal Article
Open access
PDF file
SBSévérine de Bruijn
Sévérine de Bruijn
SASébastien Anguille
Sébastien Anguille
JVJoris Verlooy
Joris Verlooy
ESEvelien Smits
Evelien Smits
VTViggo Van Tendeloo
Viggo Van Tendeloo
ELEva Lion
Eva Lion
Dendritic cell-based and other vaccination strategies that use the patient’s own immune system for the treatment of cancer are gaining momentum. Most studies of therapeutic cancer vaccination have been performed in adults. However, since cancer is one of the leading causes of death among children past infancy in the Western world, the hope is that this form of active specific immunotherapy can play an important role in the pediatric population as well. Since children have more vigorous and adaptable immune systems than adults, therapeutic cancer vaccines are expected to have a better chance of creating protective immunity and preventing cancer recurrence in pediatric patients. Moreover, in contrast to conventional cancer treatments such as chemotherapy, therapeutic cancer vaccines are designed to specifically target tumor cells and not healthy cells or tissues. This reduces the likelihood of side effects, which is an important asset in this vulnerable patient population. In this review, we present an overview of the different therapeutic cancer vaccines that have been studied in the pediatric population, with a main focus on dendritic cell-based strategies. In addition, new approaches that are currently being investigated in clinical trials are discussed to provide guidance for further improvement and optimization of pediatric cancer vaccines.

3 September 2019 in Acta Clinica Belgica
Verified
Journal Article
Closed access
SBSévérine de Bruijn
Sévérine de Bruijn
XGXavier Galloo
Xavier Galloo
GKGilles De Keulenaer
Gilles De Keulenaer
EPEdgard A. Prihadi
Edgard A. Prihadi
CBChristiane Brands
Christiane Brands
MHMark Helbert
Mark Helbert
Differential diagnosis between hypertrophic cardiomyopathy (HCM) and cardiac amyloidosis (CA) is mandatory since the prognosis is very different, but not always possible as both diseases present with increased myocardial thickness and mass. Despite better knowledge of the pathophysiology of both HCM and CA, and new developments in diagnosis, many patients with cardiac involvement in systemic amyloidosis are still only diagnosed in an advanced stage. Improvements in non-invasive diagnostic methods such as ultrasound techniques and cardiac magnetic resonance imaging will eventually obviate the need for invasive studies in order to prove amyloid cardiomyopathy. Nevertheless, today, an endomyocardial biopsy still remains the golden standard. We present an 86-year-old man, diagnosed with hypertrophic cardiomyopathy, in whom echocardiography and cardiac magnetic resonance imaging strongly suggested amyloidosis to be the underlying cause. Interestingly, a new variant of the junctophilin 2 (JPH2) gene, related to hypertrophic cardiomyopathies, was found in our patient.

21 February 2017 in Acta Clinica Belgica
Verified
Journal Article
Closed access
SBSévérine de Bruijn
Sévérine de Bruijn
CKChris Kenyon
Chris Kenyon
NLNicolas Léonard
Nicolas Léonard
EVErika Vlieghe
Erika Vlieghe
Background: Neurosyphilis is the result of an infection of the central nervous system caused by the spirochete Treponema pallidum. Its clinical presentation includes meningovascular syphilis, tabes dorsalis, and dementia paralytica, resulting in a wide range of symptoms such as psychosis, Parkinsonism, and depression. Case report: A 49-year-old male was admitted to a psychiatric hospital because of social withdrawal and self-neglect, indicative of a major depression. A routine HIV-test was positive and resulted in an admission to the Antwerp University Hospital. Clinical examination showed Argyll Robertson pupils, a wide-based gait, absence of vibration sense in the lower limbs, and a MMSE-score of 25/30. Blood analysis revealed a CD4+ count of 99 cells/μL and a HIV viral load of 2,13 × 105 copies/mL plasma. A serum TPHA (T. pallidum hemagglutination assay) titre of 1/20480 and RPR (rapid plasma reagin) titre of 1/128 were detected. TPHA and RPR titre in the cerebrospinal fluid were, respectively, 1/10240 and 1/4. A brain MRI showed diffuse cortical atrophy and lesions in the white matter compatible with HIV-encephalopathy. The diagnoses of advanced HIV-infection and late neurosyphilis were made. HAART (highly active antiretroviral therapy) and high-dose IV penicillin G were started. Conclusion: In all patients with new-onset dementia or untreatable psychosis, neurosyphilis should always be considered. Argyll Robertson pupils are regarded as pathognomonic of neurosyphilis. The management of neurosyphilis includes high-dose IV benzyl penicillin for 10 to 14 days. Close follow-up including a lumbar puncture after 6 months is warranted to ensure treatment recovery.

1 January 2025 in Case Reports in Gastrointestinal Medicine
Verified
Journal Article
Open access
SBSévérine de Bruijn
Sévérine de Bruijn
AWAnnick De Weerdt
Annick De Weerdt
GBGlenn Broeckx
Glenn Broeckx
MSMaarten Spinhoven
Maarten Spinhoven
RPRudi De Paep
Rudi De Paep
PJPhilippe G. Jorens
Philippe G. Jorens
Introduction: Cystic echinococcosis, also known as hydatid cyst, is a parasitic infection of mammals that can affect any organ. Although the diagnosis of primary splenic echinococcosis is challenging, especially in nonendemic areas, it can be life‐saving because an anaphylactic shock may occur when the cyst ruptures. Recommendations regarding optimal treatment options after rupture are scarce, and the overall prognosis remains poor. Case Presentation: A patient with a spontaneous rupture of an isolated splenic hydatid cyst was treated with splenectomy and peritoneal lavage with a hypertonic salt solution. The patient survived despite rapidly progressive hypernatremia, which was treated with conventional therapy along with continuous venovenous hemofiltration with gradient sodium replacement. Discussion: When the decision is made to treat a patient with a spontaneously ruptured splenic echinococcus cyst, splenectomy is the only surgical option. Hypernatremia is a complication to be expected when hypertonic saline is used to rinse the splenic and abdominal cavities. Conclusion: This case highlights the importance of prompt surgical intervention and the management of hypernatremia in patients with ruptured splenic hydatid cysts.